Rapport Announces Proposed Public Offering of Common Stock
Rapport Therapeutics (NASDAQ:RAPP), a clinical-stage biotech company focused on neurological and psychiatric disorder treatments, has announced a proposed public offering of $250.0 million of common stock. The company will grant underwriters a 30-day option to purchase up to an additional $37.5 million of shares.
The offering will be managed by joint book-runners Goldman Sachs, Jefferies, TD Cowen, and Stifel. The securities will be offered through an effective shelf registration statement previously filed with the SEC. The completion of the offering is subject to market conditions, with no guarantee of final terms or completion.
Rapport Therapeutics (NASDAQ:RAPP), una biotech in fase clinica specializzata in trattamenti per disturbi neurologici e psichiatrici, ha annunciato una proposta di offerta pubblica di 250,0 milioni di dollari di azioni ordinarie. La società concederà agli intermediari un'opzione di 30 giorni per acquistare fino a ulteriori 37,5 milioni di dollari di azioni.
L'offerta sarà gestita congiuntamente dai book-runner Goldman Sachs, Jefferies, TD Cowen e Stifel. I titoli saranno offerti tramite una dichiarazione di registrazione sul modulo shelf già efficace e precedentemente depositata presso la SEC. Il completamento dell'offerta dipende dalle condizioni di mercato e non vi è garanzia sui termini finali o sull'effettiva conclusione.
Rapport Therapeutics (NASDAQ:RAPP), una biotecnológica en fase clínica centrada en tratamientos para trastornos neurológicos y psiquiátricos, ha anunciado una propuesta de oferta pública de 250,0 millones de dólares de acciones ordinarias. La compañía otorgará a los colocadores una opción de 30 días para adquirir hasta 37,5 millones de dólares adicionales en acciones.
La oferta será gestionada por los colocadores conjuntos Goldman Sachs, Jefferies, TD Cowen y Stifel. Los títulos se ofrecerán mediante una declaración de registro en shelf ya efectiva y previamente presentada ante la SEC. La realización de la oferta está sujeta a las condiciones del mercado y no garantiza los términos finales ni su conclusión.
Rapport Therapeutics (NASDAQ:RAPP)는 신경 및 정신 질환 치료제에 주력하는 임상 단계의 바이오텍으로, 보통주 2억5000만 달러 규모의 공모를 제안했다고 발표했습니다. 회사는 인수단에게 추가로 최대 3750만 달러어치 주식을 30일간 매입할 수 있는 옵션을 부여합니다.
이번 공모는 공동 주관사인 Goldman Sachs, Jefferies, TD Cowen, Stifel이 관리합니다. 증권은 이미 SEC에 제출되어 효력이 발생한 shelf 등록명세서를 통해 제공됩니다. 공모의 완료는 시장 여건에 따라 달라지며 최종 조건이나 완료가 보장되지는 않습니다.
Rapport Therapeutics (NASDAQ:RAPP), une société de biotechnologie en phase clinique spécialisée dans les traitements des troubles neurologiques et psychiatriques, a annoncé une proposition d'offre publique de 250,0 millions de dollars d'actions ordinaires. La société accordera aux souscripteurs une option de 30 jours pour acheter jusqu'à 37,5 millions de dollars supplémentaires d'actions.
L'offre sera gérée par les chefs de file conjoints Goldman Sachs, Jefferies, TD Cowen et Stifel. Les titres seront proposés via une déclaration d'enregistrement shelf déjà effective et préalablement déposée auprès de la SEC. La réalisation de l'offre est soumise aux conditions de marché et il n'existe aucune garantie quant aux termes définitifs ou à l'achèvement.
Rapport Therapeutics (NASDAQ:RAPP), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf Behandlungen neurologischer und psychiatrischer Störungen konzentriert, hat ein vorgeschlagenes öffentliches Angebot von 250,0 Millionen US-Dollar an Stammaktien angekündigt. Das Unternehmen gewährt den Underwritern eine 30-tägige Option zum Erwerb weiterer Aktien im Umfang von bis zu 37,5 Millionen US-Dollar.
Die Platzierung wird von den Joint Book-Runnern Goldman Sachs, Jefferies, TD Cowen und Stifel betreut. Die Wertpapiere werden über eine bereits wirksame Shelf-Registrierung angeboten, die zuvor bei der SEC eingereicht wurde. Der Abschluss des Angebots hängt von den Marktbedingungen ab; es gibt keine Garantie für endgültige Konditionen oder die Durchführung.
- Access to significant capital with $250.0 million base offering
- Additional upside potential through $37.5 million overallotment option
- Strong underwriter syndicate including major investment banks
- Potential dilution for existing shareholders
- Stock price pressure due to increased share supply
- Uncertainty regarding final offering terms and completion
Insights
Rapport Therapeutics is raising $250M through public stock offering, potentially diluting existing shareholders while boosting its clinical-stage development capabilities.
Rapport Therapeutics (RAPP) has announced plans to raise
The size of this offering is significant relative to clinical-stage biotechs, indicating the company likely requires substantial capital to advance its small molecule precision medicine pipeline. Without current marketed products generating revenue, biotechs typically fund operations through capital raises like this one. The offering is being managed by premier investment banks including Goldman Sachs, Jefferies, TD Cowen, and Stifel, providing credibility to the transaction.
For existing shareholders, this offering will likely result in dilution of their ownership percentage and potentially place downward pressure on the stock price in the near term. However, if the capital is deployed effectively to advance promising clinical candidates, long-term value creation may offset this dilution. The company's effective shelf registration statement (filed July 2025) demonstrates forward financial planning, allowing for this relatively quick capital raise when market conditions were deemed favorable.
Investors should carefully review the forthcoming prospectus supplement for details on the company's current cash position, burn rate, and specific intended uses of proceeds to better evaluate the strategic necessity and potential impact of this financing.
BOSTON and SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it has commenced an underwritten public offering of
Goldman Sachs & Co. LLC, Jefferies, TD Cowen and Stifel are acting as joint book-running managers for the proposed offering.
The securities are being offered by Rapport pursuant to an effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (SEC) on July 1, 2025 and declared effective by the SEC on July 9, 2025 (File No. 333-288444). A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the proposed offering will be filed with the SEC and may be obtained, when available, from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at Prospectus-ny@ny.email.gs.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, by telephone at (833) 297-2926, or by email at TD.ECM_Prospectus@tdsecurities.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com.; or by accessing the SEC’s website at www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological or psychiatric disorders. The Company’s founders have made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain. Their findings form the basis of Rapport’s RAP technology platform, which enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline includes the Company’s lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The Company is currently pursuing RAP-219 as a potential treatment for drug-resistant focal onset seizures, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Rapport’s anticipated public offering. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will” and “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions and statements regarding the timing, size and expected gross proceeds of the offering, the satisfaction of customary closing conditions related to the offering and sale of securities, the grant to the underwriters of an option to purchase additional shares and Rapport’s ability to complete the offering. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Rapport’s most recent annual report on Form 10-K and quarterly report on Form 10-Q filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Rapport’s other filings with the SEC, including those contained or incorporated by reference in the preliminary prospectus supplement and accompanying prospectus related to the proposed offering to be filed with the SEC. Any forward-looking statements contained in this press release represent Rapport’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Rapport explicitly disclaims any obligation to update any forward-looking statements, except as required by law.
Contact
Julie DiCarlo
Head of Communications & IR
Rapport Therapeutics
jdicarlo@rapportrx.com
FAQ
How much is Rapport Therapeutics (RAPP) planning to raise in its public offering?
Who are the underwriters for Rapport's (RAPP) public offering?
What will Rapport Therapeutics use the offering proceeds for?
When was Rapport's shelf registration statement declared effective by the SEC?
What type of company is Rapport Therapeutics (RAPP)?
